Építés alatt – nem éles oldal

Ugrás a tartalomra

Frontlight Research

Vizsgálati helyszín

Clintrial s.r.o.

Prague 10, 100 00, CsehországEU-13 felzárkózó országMég nincs intézményhez kötve

33futó vizsgálat
35lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 69 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Atópiás dermatitisz (ekcéma)21 vizsgálat
Depresszió13 vizsgálat
Pikkelysömör12 vizsgálat
Alzheimer-kór6 vizsgálat
Migrén6 vizsgálat
Arthritis psoriatica3 vizsgálat
Skizofrénia3 vizsgálat
Rheumatoid arthritis2 vizsgálat
Alopecia areata1 vizsgálat
Hidradenitis suppurativa1 vizsgálat
Insomnia1 vizsgálat
Mild cognitive impairment1 vizsgálat
és még 2
Fázis: 3. fázis34 vizsgálat
2. fázis30 vizsgálat
2/3. fázis3 vizsgálat
1. fázis1 vizsgálat
4. fázis1 vizsgálat
Állapot: Lezárult34 vizsgálat
Toboroz16 vizsgálat
Fut, nem toboroz12 vizsgálat
Még nem toboroz5 vizsgálat
Felfüggesztve1 vizsgálat
Visszavonták1 vizsgálat
Fő szponzor: AbbVie6 vizsgálat
Takeda5 vizsgálat
Intra-Cellular Therapies, Inc.3 vizsgálat
Sanofi3 vizsgálat
ACADIA Pharmaceuticals Inc.2 vizsgálat
és még 43

Futó vizsgálatok

Még nem toboroz
A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis
2026-526485-25-00· 2. fázis· Triveni Bio Inc.· Forrás
Még nem toboroz
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· 3. fázis· Hunan Mabgeek Biotech Co. Ltd.· Forrás
Még nem toboroz
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· 2. fázis· Enveda Therapeutics Inc.· Forrás
Toboroz
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
2026-525673-39-00· 2. fázis· Apollo Therapeutics Limited· Forrás
Toboroz
DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00· 2. fázis· Draig Therapeutics Limited· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Toboroz
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
NCT07441395· 2. fázis· Corvus Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· 2. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· 3. fázis· Newron Pharmaceuticals S.p.A.· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Toboroz
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· 2. fázis· Apogee Therapeutics Inc.· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Meghívásos bevonás
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700· 2. fázis· Seaport Therapeutics· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240· 2. fázis· Seaport Therapeutics· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Toboroz
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Toboroz
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044· 3. fázis· Vanda Pharmaceuticals· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595· 3. fázis· Definium Therapeutics US, Inc.· Forrás
Toboroz
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624· 3. fázis· Neurocrine Biosciences· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Fut, nem toboroz
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Toboroz
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383· 2. fázis· Intra-Cellular Therapies, Inc.· Forrás
Toboroz
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· 2. fázis· Apogee Therapeutics, Inc.· Forrás
Meghívásos bevonás
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NCT06194799· 3. fázis· ACADIA Pharmaceuticals Inc.· Forrás
Toboroz
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Fut, nem toboroz
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777· 2. fázis· Sanofi· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
A Study Evaluating BFB759 in Atopic Dermatitis
2025-521624-30-00· 2. fázis· Bluefin Biomedicine Inc.· Forrás
Lezárult
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT06973291· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
NCT07076407· 3. fázis· Xenon Pharmaceuticals Inc.· Forrás
Fut, nem toboroz
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· 3. fázis· AbbVie· Forrás
Lezárult
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT06790121· 2. fázis· Sanofi· Forrás
Lezárult
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· 3. fázis· Janssen Cilag International· Forrás
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine
2023-507942-10-00· 2. fázis· Boehringer Ingelheim International GmbH· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Lezárult
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis
2023-503522-40-01· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· 2. fázis· H. Lundbeck A/S· Forrás
Lezárult
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· 3. fázis· AbbVie· Forrás
Toboroz
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311· 3. fázis· medac GmbH· Forrás
Lezárult
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· 1. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Toboroz
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673· 2/3. fázis· ACADIA Pharmaceuticals Inc.· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· 3. fázis· Takeda· Forrás
Lezárult
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· 3. fázis· Amgen Inc.· Forrás
Lezárult
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· 3. fázis· AbbVie· Forrás
Lezárult
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099· 2. fázis· LEO Pharma· Forrás
Lezárult
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· 3. fázis· Neurocrine Biosciences Inc.· Forrás
Lezárult
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· 3. fázis· Janssen Cilag International· Forrás
Lezárult
A Trial of GH001 in Patients With Treatment-resistant Depression
NCT05800860· 2. fázis· GH Research Ireland Limited· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
NCT05896527· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Lezárult
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
2022-500538-27-00· 2/3. fázis· Otsuka Pharmaceutical Development And Commercialization Inc.· Forrás
Lezárult
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239· 2. fázis· Recognify Life Sciences· Forrás
Lezárult
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
NCT05398445· 3. fázis· Amgen· Forrás
Lezárult
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· 2. fázis· Inmune Bio, Inc.· Forrás
Lezárult
Open-label Trial in Parkinson's Disease (PD)
NCT04760769· 3. fázis· AbbVie· Forrás
Lezárult
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· 3. fázis· AbbVie· Forrás
Lezárult
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· 3. fázis· Galderma R&D· Forrás
Lezárult
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457· 3. fázis· Pfizer· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· 4. fázis· Eli Lilly and Company· Forrás

Helyszínadatok: EU CTIS (euclinicaltrials.eu)Frissítve: 2026. nov. 15.

Építés alatt, nem éles – Clintrial s.r.o.: vizsgálati helyszín – Frontlight Research